Cardiovascular outcomes trials of diabetes drugs have led to label expansions and guideline endorsements. Do you recall the studies and the outcomes? Find out, here.
Recent FDA-mandated cardiovascular outcomes trials of the sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have revealed both cardio- and renal- protective properties in patient with type 2 diabetes. Based on these studies, several agents now carry expanded indications.In the following 5 questions on these studies and their outcomes, you will know the names of the drugs and the trials, but do you remember which study supports the labeling change for which drug? Find out, and good luck.
Although the mechanism underlying the pleiotropic effects observed is not yet clear, the American Diabetes Association now recommends that patients with T2D and cardiovascular disease (CVD) whose glucose control is inadequate despite treatment with metformin should receive an agent from one of these classes. More on the results can be found in each answer.
1. Which of the above has received FDA approval to decrease the progression of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D)?
2. The FDA expanded the indication of dapagliflozin to include reduced risk for hospitalization for heart failure (HF) in adults with T2D and established CVD or multiple CV risk factors based on the results of which of the trials above?
3. In addition to treating diabetes, which of the GLP-1 receptor agonists above is FDA-approved for reducing the risk of major CV events in adults with T2D and established CVD?